Literature DB >> 16818615

Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma.

Yu-Jen Chen1, Vicky Hakin-Smith, Mario Teo, George E Xinarianos, David A Jellinek, Thomas Carroll, David McDowell, Martin R MacFarlane, Ronald Boet, Bruce C Baguley, Antony W Braithwaite, Roger R Reddel, Janice A Royds.   

Abstract

The molecular basis for alternative lengthening of telomeres (ALT), a prognostic marker for glioma patients, remains unknown. We examined TP53 status in relation to telomere maintenance mechanism (TMM) in 108 patients with glioblastoma multiforme and two patients with anaplastic astrocytoma from New Zealand and United Kingdom. Tumor samples were analyzed with respect to telomerase activity, telomere length, and ALT-associated promyelocytic leukemia nuclear bodies to determine their TMM. TP53 mutation was analyzed by direct sequencing of coding exons 2 to 11. We found an association between TP53 mutation and ALT mechanism and between wild-type TP53 and telomerase and absence of a known TMM (P < 0.0001). We suggest that TP53 deficiency plays a permissive role in the activation of ALT.

Entities:  

Mesh:

Year:  2006        PMID: 16818615     DOI: 10.1158/0008-5472.CAN-06-0910

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.

Authors:  Tania Slatter; Jennifer Gifford-Garner; Anna Wiles; Xin Tan; Yu-Jen Chen; Martin MacFarlane; Michael Sullivan; Janice Royds; Noelyn Hung
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade.

Authors:  Sandra Sampl; Sibylle Pramhas; Christian Stern; Matthias Preusser; Christine Marosi; Klaus Holzmann
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

Review 3.  Molecular characteristics of pediatric high-grade gliomas.

Authors:  Omar Chamdine; Amar Gajjar
Journal:  CNS Oncol       Date:  2014-11

4.  Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database.

Authors:  Lyubov E Salnikova
Journal:  Neuromolecular Med       Date:  2014-01-31       Impact factor: 3.843

Review 5.  Means to the ends: The role of telomeres and telomere processing machinery in metastasis.

Authors:  Nathaniel J Robinson; William P Schiemann
Journal:  Biochim Biophys Acta       Date:  2016-10-18

6.  ALTernative Telomere Maintenance and Cancer.

Authors:  Robert L Dilley; Roger A Greenberg
Journal:  Trends Cancer       Date:  2015-10-01

7.  MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication.

Authors:  J Zhou; M V Reddy; B K J Wilson; D A Blair; A Taha; C M Frampton; R A Eiholzer; P Y C Gan; F Ziad; Z Thotathil; S Kirs; N A Hung; J A Royds; T L Slatter
Journal:  AJNR Am J Neuroradiol       Date:  2017-11-30       Impact factor: 3.825

8.  Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma.

Authors:  Noelyn A Hung; Ramona A Eiholzer; Stenar Kirs; Jean Zhou; Kirsten Ward-Hartstonge; Anna K Wiles; Chris M Frampton; Ahmad Taha; Janice A Royds; Tania L Slatter
Journal:  Mod Pathol       Date:  2016-01-15       Impact factor: 7.842

9.  Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features.

Authors:  Laura D Wood; Christopher M Heaphy; Hubert Darius-J Daniel; Bita V Naini; Charles R Lassman; May R Arroyo; Ihab R Kamel; David P Cosgrove; John K Boitnott; Alan K Meeker; Michael S Torbenson
Journal:  Mod Pathol       Date:  2013-05-03       Impact factor: 7.842

10.  A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT.

Authors:  K Lafferty-Whyte; C J Cairney; M B Will; N Serakinci; M-G Daidone; N Zaffaroni; A Bilsland; W N Keith
Journal:  Oncogene       Date:  2009-08-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.